Ranbaxy extends branded Diovan's life

Share this article:

Four Ranbaxy sites are on the FDA's list of black sites, and while this may seem like bad news for the Sun Pharma subsidiary, the division's manufacturing slip-ups have been to Novartis's benefit: Bloomberg reports that because of the way generic licenses are granted, license-holder Ranbaxy's paralysis has kept generic Diovan off the market, which means Novartis's branded Diovan remains king of the pharmacy.

As Bloomberg explains, the law is that the generics license is Ranbaxy's and competitors can't join the blood pressure medication fray until its generic has had six months in the market. Only thing is, the FDA has not approved the generic, which puts Ranbaxy's generic and therefore other manufacturer generics in limbo.

By Bloomberg's count, this delay translates into around $900 million in lost consumer savings.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.